Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 7;28(12):1927–1936. doi: 10.1177/13524585221097561

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2022

This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 2. — Treatment effect on thalamic volume loss over time in the RMS (a) and PPMS (b) populations.

BL, baseline; IFNβ1a, interferon β-1a; OCR, ocrelizumab; OLE, open-label extension; PBO, placebo; SE, standard error. Gray box in (b) represents the transition period of PPMS patients switching from placebo to ocrelizumab and entering the OLE from the extended controlled period. Percentage reductions reported in the figure were calculated as: 100 × (ocrelizumab adjusted mean—comparator arm adjusted mean)/(comparator arm adjusted mean).